From: Early and midterm outcomes of a bentall operation using an all-biological valved BioConduit™
No HVD at 1 year n = 64 | Moderate or severe HVD at 1 year n = 10 | p Value | |
---|---|---|---|
Characteristics | |||
Age (years) | 71 ± 11 | 72 ± 10 | 0.75 |
Female gender | 14 (22%) | 5 (50%) | 0.11 |
AHT | 41 (64%) | 9 (90%) | 0.15 |
Diabetes | 11 (17%) | 2 (20%) | 1 |
Renal insufficiency (GFR < 60 ml/min) | 8 (12%) | 4 (40%) | 0.05 |
Marfan’s syndrome | 1(2%) | 0 (0%) | 1 |
Preoperative LVEF (%) | 56 ± 10 | 51 ± 7 | 0.07 |
Indication | |||
Ascending aortic aneurysm | 48 (75%) | 9 (90%) | 0.43 |
Type A aortic dissection | 5 (8%) | 1 (10%) | 1 |
Acute endocarditis | 11(17%) | 0 (0%) | 0.34 |
Aortic valve regurgitation | 29 (45%) | 7 (70%) | 0.18 |
Aortic stenosis | 13 (20%) | 4 (40%) | 0.22 |
Bicuspid aortic valve | 21 (33%) | 4 (40%) | 0.72 |
Surgical data | |||
Emergency | 10 (16%) | 1 (10%) | 1 |
Redo Surgery | 17 (26%) | 0 (0%) | 0.10 |
CPB time (min, mean) | 112 ± 50 | 103 ± 40 | 0.55 |
Aortic cross clamp time (min, mean) | 87 ± 40 | 81 ± 32 | 0.76 |
CABG | 14 (22%) | 2 (20%) | 1 |
Mitral valve procedure (repair/replacement) | 3 (5%) | 0 (0%) | 1 |
Tricuspid annuloplasty | 2 (3%) | 0 (0%) | 1 |
AF ablation and Left Atrial Appendage Closure | 3 (5%) | 1 (10%) | 0.44 |
Combination | 28 (44%) | 3 (30%) | 0.50 |
Size of graft implanted | 26 ± 2 | 25 ± 2 | < 0.01 |
23/ 25 mm graft | 21 (33%) | 8 (80%) | 0.01 |
Interrupted single, everting, pledged, reinforced U-stiches (intra-annular level) (vs Interrupted single, non-everting, pledged, reinforced U-stiches (supra-annular level) | 40 (62%) | 8 (80%) | 0.47 |
Echocardiographic data | |||
Post-operative Vmax (m/s) | 2.2 ± 0.5 | 2.5 ± 0.5 | 0.06 |
Post-operative Mean gradient (mmHg) | 12 ± 6 | 15 ± 6 | 0.11 |
Post-operative aortic valve effective surface area (cm2) | 1.8 ± 0.5 | 1.8 ± 0.6 | 0.99 |
Post-operative indexed aortic effective surface area (cm2/m2) | 1 ± 0.2 | 0.9 ± 0.3 | 0.91 |
1 Year Vmax (m/s) | 2.3 ± 0.4 | 3.7 ± 0.7 | < 0.01 |
1 Year Mean gradient (mmHg) | 12 ± 5 | 35 ± 14 | < 0.01 |
1 Year aortic valve effective surface area (cm2) | 1.5 ± 0.5 | 0.8 ± 0.3 | < 0.01 |
1 Year aortic indexed effective surface area (cm2/m2) | 0.8 ± 0.3 | 0.5 ± 0.1 | < 0.01 |
1 Year LVEF (%) | 58 ± 11 | 59 ± 6 | 1 |